Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 146 affiliates and a total of more than 47,700 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.
Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative "Making more Health" and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability.
In 2014, Boehringer Ingelheim achieved net sales of about 13.3 billion euros. R&D expenditure corresponds to 19.9 per cent of its net sales.
Business & Industry
- GSK and Vir Biotechnology announce United States government agreement to purchase additional supply of sotrovimab
- New Vaxzevria data further support its use as third dose booster
- Novartis and Molecular Partners report positive topline data from Phase 2 study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19
- Amgen and Arrakis Therapeutics announce multi-target collaboration to identify novel RNA degrader small molecule therapeutics
- Bayer and Mammoth Biosciences to collaborate on novel gene editing technolog
Research & Development
- WHO recommends two new drugs to treat patients with COVID-19
- Research team finds new dual benefit mode of action for a drug candidate to fight COVID-19
- COVID-19 - Omicron: resistant to most monoclonal antibodies but neutralized by a booster dose
- COVID-19 can trigger self-attacking antibodies
- Treatments in weeks, not months: Scientists develop ambitious pandemic response plan
- Scientists identify antibodies that can neutralize omicron
- Stopping dementia at the nose with combination of rifampicin and resveratrol
Conferences & Events
- New vaccine ingredient shows promise
- Modernise your Medical Affairs Insight Management with ViiV Healthcare, Eisai, ASC Therapeutics and Within3
- Novartis, Bayer and Boehringer Ingelheim to showcase their commitment to a reimagined pharma industry
- Scientists urge for investment now in highly potent vaccines to prevent the next pandemic
- CPhI Worldwide to return in 2021
- Reuters Events' Cell & Gene Therapy USA
- Total health: Build a better healthcare system
Regulatory Affairs
- FDA authorizes additional oral antiviral for treatment of COVID-19 in certain adults
- FDA authorizes first oral antiviral for treatment of COVID-19
- FDA expands eligibility for Pfizer-BioNTech COVID-19 booster dose to 16- and 17-year-olds
- FDA authorizes Pfizer-BioNTech COVID-19 vaccine for emergency use in children 5 through 11 years of age
- FDA, NIH, and 15 private organizations join forces to increase effective gene therapies for rare diseases